Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 10/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17698452 | 0.78 | CHRNB2 (0.40) | NPY5RCA1CA2CHRNB2CHRNB4 | |
| SCHEMBL3274019 | 0.78 | CA1 (0.39) | NPY5RCA1CA2NPY2RLTA4H | |
| SCHEMBL1206432 | 0.68 | KDM4E (0.52) | CHRNB2CHRNB4CHRNA3CHRNA4KDM4E | |
| SCHEMBL817422 | 0.68 | KDM4E (0.52) | CHRNB2CHRNB4CHRNA3CHRNA4KDM4E | |
| SCHEMBL1205734 | 0.68 | KDM4E (0.52) | CHRNB2CHRNB4CHRNA3CHRNA4KDM4E | |
| SCHEMBL5398515 | 0.65 | CHRNB2 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4KDM4E | |
| SCHEMBL28144242 | 0.65 | CHRNB2 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4KDM4E | |
| SCHEMBL9995387 | 0.65 | CHRNB2 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4KDM4E | |
| SCHEMBL12071516 | 0.65 | CHRNB2 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4KDM4E | |
| SCHEMBL28144244 | 0.65 | CHRNB2 (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | claimed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1961756-A1 | NOVEL BISBORON COMPOUND | Japan Science and Technology Agency (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | KCNMB4, CA2, NR0B2 | NPY5R 102/4885CA1 393/4885CA2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.